Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Venclyxto

- PMLiVE

Roche launches Bluetooth coagulation testing system

New CoaguChek device can wirelessly transmit test data to a patient's clinic

- PMLiVE

Trial of AbbVie’s Rova-T disappoints at ASCO

But company says the modest trial data is “a good early sign” for lung cancer drug

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Roche Basel Switzerland

Roche’s Tecentriq works as first-line bladder cancer therapy

New trial data presented at ASCO supports wider use of the drug

- PMLiVE

Roche picks up European rights to diabetes implant

Will distribute Senseonics' Eversense CGM System in Germany, Italy and the Netherlands

EU flag

Imbruvica wins wider European leukaemia licence

AbbVie and J&J’s first-in-class drug now approved to treat all CLL patients in the EU

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

Roche Basel Switzerland

Roche gets first approval for PD-L1 inhibitor Tecentriq

Expects to launch bladder cancer treatment within the next two weeks

Allergan logo

Allergan on course to file uterine fibroid drug next year

New drug could be safer and more effective than existing treatment

Deal Watch March 2016

AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links